Why the study?
Does enalapril maleate effectively inhibit angiotensin converting enzyme activity in infants with congestive heart failure?
Does enalapril maleate effectively inhibit angiotensin converting enzyme activity in infants with congestive heart failure?
Enalapril maleate effectively inhibits ACE activity in infants with congestive heart failure, demonstrating a pharmacodynamic profile similar to that seen in adults.
Answers are grounded in this paper and cite their sources.
May inform enalapril dosing in infants with CHF; extends adult data but leaves open outcome trials.
We studied the inhibition of angiotensin converting enzyme (ACE) in eight infants with congestive heart failure (CHF) poorly controlled with digoxin and diuretics, treated orally with 0.25 mg kg-1 enalapril maleate once a day. Baseline ACE activities were compared between these infants and control children without CHF or ACE inhibitor. Except for one infant who vomited, inhibition of ACE activity was 75.5 +/- 12.2%, 75.5 +/- 10.5% and 51.7 +/- 12.2%, at 4, 12 and 24 h after drug intake respectively. There was no correlation between postnatal age and inhibition of ACE activity. In infants with CHF, mean baseline ACE activity was significantly higher than in control infants (36.4 +/- 7.2 mu ml-1 vs 26.9 +/- 6.9 mu ml-1, P < 0.05). These results were very similar to those seen in adults.
No takes yet. Share an insight, caveat, or question.
Dutertre et al. (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: